Janku Filip 4

4 · Monte Rosa Therapeutics, Inc. · Filed Jun 25, 2026

AI-generated summary of this filing

Updated Jun 25, 2026

Monte Rosa (GLUE) CMO Filip Exercises Options and Sells Shares

What Happened

Filip Janku, Chief Medical Officer of Monte Rosa Therapeutics (GLUE), exercised options to acquire 36,000 shares (6,000 on 6/23 and 30,000 on 6/24) at $7.56 per share (cost = $272,160). He also sold 41,845 shares in open-market transactions (11,845 on 6/23 and 30,000 on 6/24) for aggregate proceeds of approximately $882,203. Sales were done under a Rule 10b5-1 trading plan.

Key Details

Transaction dates and prices:
- 2026-06-23: Exercised 6,000 shares @ $7.56 (acq. $45,360); sold 11,845 shares @ weighted avg $20.22 (proceeds $239,522). Sales prices ranged $19.95–$20.50 per F2.
- 2026-06-24: Exercised 30,000 shares @ $7.56 (acq. $226,800); sold 30,000 shares @ weighted avg $21.42 (proceeds $642,681). Sales prices ranged $21.30–$21.59 per F3.
- Two additional derivative-line entries show disposals at $0.00 (6,000 and 30,000) — these reflect the conversion/settlement of derivative instruments upon exercise rather than market sales.
Total cash paid to exercise options: $272,160. Total cash received from open-market sales: ~$882,203.
Footnotes: F1 — sales were effected under a 10b5-1 plan adopted March 4, 2026; F4 — the exercised options were fully vested and exercisable.
Filing: Form 4 filed 2026-06-25 for transactions on 6/23–6/24 (appears timely; no late filing indicated).
Shares owned after the transactions: not specified in the provided summary.

Context

This was an option exercise combined with open-market sales. The exercised shares appear to have been at least partly sold; total shares sold (41,845) exceed the 36,000 newly acquired, so some sold may have come from prior holdings. Exercises of vested options are routine for insiders; open-market sales under a prearranged 10b5-1 plan are typically automated, not necessarily a directional signal about company prospects.
If you want the exact breakdown of how many shares sold at each price within the reported ranges, the filer notes they will provide that on request to the company, shareholders, or the SEC.

Form 4

Period: 2026-06-23

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-06-23$7.56/sh+6,000$45,360→ 71,837 total
Sale
Common Stock
[F1][F2]
2026-06-23$20.22/sh−11,845$239,522→ 59,992 total
Exercise/Conversion
Common Stock
[F1]
2026-06-24$7.56/sh+30,000$226,800→ 89,992 total
Sale
Common Stock
[F1][F3]
2026-06-24$21.42/sh−30,000$642,681→ 59,992 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-06-23−6,000→ 96,000 total
Exercise: $7.56Exp: 2032-10-03→ Common Stock (6,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-06-24−30,000→ 66,000 total
Exercise: $7.56Exp: 2032-10-03→ Common Stock (30,000 underlying)

Footnotes (4)

[F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F4]The shares underlying this option are fully vested and exercisable.

Signature

/s/ Phil Nickson, Attorney-in-Fact|2026-06-25

2 files